secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLAUKOS Corp (GKOS)
CIK:        0001192448
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001104659-26-003321
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Glaukos reports preliminary Q4 2025 net sales ~$143M (+36% YoY); reaffirms FY2026 guidance $600-620M
--------------------------------------------------------------------------------

- Q4 2025 net sales ~$143M (+36% YoY); FY2025 net sales ~$507M (+32% YoY).
- U.S. Glaucoma net sales FY2025 $299M, including iDose TR $136M; Corneal Health $86M.
- Cash & equivalents $283M, no debt at Q4 end; 2026 revenue guidance reaffirmed $600-620M.
- International Glaucoma net sales FY2025 $122M; Q4 alone ~$33M.
- Company will report full Q4 & FY2025 results on Feb 17, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/0001104659-26-003321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1192448/000110465926003321/gkos-20260113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-003321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer